Non-small cell lung cancer (NSCLC) has the largest number of identified therapeutic targets, some of which have therapeutic utility. The use of next-generation sequencing facilitates accurate molecular diagnosis and allows the detection of other emerging mutations, such as the HER2 mutation and biomarkers predictive of response to immunotherapy. In this consensus, a group of experts […]
Researchers at the University of Wisconsin School of Medicine and Public Health (Madison, WI, USA) have developed a blood test that is able to detect multiple types of cancer in a relatively simpler and less expensive way compared to other tests in development. The test detects specific signs of cancer in the blood using a
BLOOD TEST TO DETECT CANCER BY IDENTIFYING CIRCULATING TUMOR DNA Read More »
In this single-center retrospective analysis, the response of 76 patients with high-risk myelodysplastic syndrome (MDS) treated with azacitidine (AZA) was reviewed, especially the cytogenetic response (CGR) to determine the response to treatment and the possible impact of karyotype evolution (KE) on the course of the disease. So far, the only treatment option with curative potential
Patients with non-basal triple-negative breast cancer are those who benefit most from chemotherapy with oral capecitabine as adjuvant treatment, according to a new analysis of the patient population of the phase III clinical trial GEICAM/2003-11_CIBOMA/2004-01, called GEICAM/CIBOMA, carried out by GEICAM and the Ibero-American Coalition for Research in Breast Oncology (CIBOMA). The results of the study
Immunochemotherapy and the search for biomarkers mark a paradigm shift in lung cancer. The possibilities offered by these treatments in combination with conventional tools, such as chemotherapy, have doubled the five-year survival of patients, as well as the median overall survival in advanced stages. Specifically, the application of immunotherapy and chemotherapy is already a standard
This multicenter clinical trial evaluated the clinical efficacy of sequential treatments in patients with metastatic colorectal cancer with G12C mutation of the KRAS gene who received intensive first-line double or triple first-line chemotherapy (including irinotecan- or oxaliplatin-based chemotherapy). In the development of the trial, only moderate overall response rates were observed with first-line double or
In this double-blind phase III clinical trial, patients with newly diagnosed ovarian cancer and a BRCA mutation (germline or somatic) who responded to platinum-based chemotherapy were randomized to receive Olaparib or placebo for up to 2 years. After a 7-year follow-up, prespecified analysis of overall survival was reported. This is the longest follow-up of a
Sarcomas have undergone important advances in their diagnosis and treatment in recent years. For this reason, coinciding with Sarcoma Day in Spain, which is celebrated on September 20, SEOM has updated the advances in this pathology. Certain aspects of therapeutic management have been consolidated, as well as the use of certain drugs approved in recent
SEOM UPDATES ON DIAGNOSTIC AND THERAPEUTIC ADVANCES IN SARCOMAS Read More »
The incidence of brain metastases continues to increase, currently affecting 25% of cancer patients. But currently available therapies have limited efficacy and fail to improve survival limited efficacy and fail to improve survival. To address this situation, the team led by Manuel Valiente, head of the Brain Metastasis Group at the Spanish National Cancer Research
NEW DRUG SCREENING METHOD FOR THE TREATMENT OF BRAIN METASTASES Read More »
The trial conducted by Hartmut Döhner and his research group has shown that, compared to placebo, oral azacitidine improved overall survival in patients with acute myeloid leukemia (AML) in first remission after chemotherapy who were not candidates for stem cell transplantation. This analysis found that the azacitidine-associated survival improvement was independent of NPM1 and FLT3
